This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks With Recent Price Strength to Strengthen Portfolio
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?
by Zacks Equity Research
Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%
by Zacks Equity Research
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
Vanda Pharmaceuticals (VNDA) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 1900.00% and 0.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Menlo Stock Plunges on Phase II Chronic Cough Study Failure
by Zacks Equity Research
Menlo Therapeutics' (MNLO) sole pipeline candidate, serlopitant, fails to meet endpoint in a phase II study in refractory chronic cough patients. Study to be terminated.
Vanda Pharmaceuticals (VNDA) Catches Eye: Stock Jumps 8.7%
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.
Zacks.com highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon
by Zacks Equity Research
Zacks.com highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon
Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.
Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks
by Zacks Equity Research
Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.
Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.
5 Low-Beta Stocks to Take Refuge in a Volatile Market
by Zacks Equity Research
We create a strategy that clearly shows that less risky stocks can also generate handsome returns if some parameters are considered.
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.
Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
by Zacks Equity Research
Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.
Zacks.com featured highlights include: Vanda, Turtle Beach, PCM and Turning Point
by Zacks Equity Research
Zacks.com featured highlights include: Vanda, Turtle Beach, PCM and Turning Point
Vanda Pharmaceuticals (VNDA) Beats Q2 Earnings Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 600.00% and -0.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.
Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Endocyte (ECYT) initiates a phase III VISION study for its lead pipeline candidate,-177Lu-PSMA-617, during the second quarter of 2018.
4 Stocks With Recent Price Strength to Enhance Your Returns
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.
Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.
Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up
by Zacks Equity Research
ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group